89bio Inc (ETNB)
8.51
-0.02
(-0.23%)
USD |
NASDAQ |
Apr 30, 16:00
8.505
0.00 (0.00%)
After-Hours: 20:00
89bio Cash from Operations (TTM): -129.19M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -129.19M |
September 30, 2023 | -121.99M |
June 30, 2023 | -106.44M |
March 31, 2023 | -86.83M |
December 31, 2022 | -81.09M |
September 30, 2022 | -82.23M |
June 30, 2022 | -80.87M |
March 31, 2022 | -86.14M |
December 31, 2021 | -76.78M |
Date | Value |
---|---|
September 30, 2021 | -62.57M |
June 30, 2021 | -62.06M |
March 31, 2021 | -53.47M |
December 31, 2020 | -46.24M |
September 30, 2020 | -43.35M |
June 30, 2020 | -36.60M |
March 31, 2020 | -29.04M |
December 31, 2019 | -25.46M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-129.19M
Minimum
Dec 2023
-25.46M
Maximum
Dec 2019
-71.20M
Average
-76.78M
Median
Dec 2021
Cash from Operations (TTM) Benchmarks
Madrigal Pharmaceuticals Inc | -324.23M |
Akero Therapeutics Inc | -145.37M |
Viking Therapeutics Inc | -54.87M |
Galectin Therapeutics Inc | -32.96M |
Terns Pharmaceuticals Inc | -67.39M |